Strategic goal 1 business objectives table

in page functions


Strategic objective  

Programme objective  

Programme deliverable (2015)  

Lead partner  

Budget ($m) FY11  

Strategic goal 1. Accelerate the uptake and use of underused and new vaccines  

1.1. Increase evidence based decision-making by countries  


Improve country decision-making structures, systems and processes  

i) 50 Gavi supported countries have National Immunisation Technical Advisory Groups (NITAG) meeting 6 basic process indicators[1]  

ii) 25% of Gavi supported countries have functional National Regulatory Authorities (NRAs)[2]  




Ensure availability and use of high quality programmatic and epidemiological data  

Corrective action implemented in 80% of Gavi supported countries where there is greater than a 5 percentage point difference between the country DTP3 coverage estimate and the WHO/UNICEF estimate[3]  




Improve scientific knowledge, and raise awareness amongst stakeholders

100% of priority scientific studies completed or on target for completion and a total of 25 communication packets[4] developed to support specific events



1.2. Strengthen country introduction to help meet demand  


Improve the quality of country planning[5], GAVI applications and performancereporting  

All Gavi countries have updated their Independent Review Committee-endorsed introduction plans and regularly report on implementation and performance[6]  




Prepare countries for successful introductions[7]of new and underused vaccines

All Gavi supported countries have undertaken Effective Vaccine Management (EVM) assessments, developed relevant improvement initiatives and prepared for successful introductions




Meet established quality indicators[8] for surveillance of diseases preventable by new and underused vaccines

i) 60% of countries have sentinel surveillance systems meeting established quality standards

ii) 30 countries have functioning national Adverse Events Following Immunisation committees for addressing vaccine safety alerts and significant safety issues




Strengthen national capacity for planning of behaviour change communication
for new and underused vaccines within a country's disease control framework

25 priority countries have implemented coordinated communication
plans and demonstrated impact on 1-3 priority targeted behaviours




[1]19 of the 72 Gavi-eligible countries had a National Immunisation Technical Advisory Group (NITAG) according to a 2008 WHO survey, of which only 2 had a NITAG meeting all 6 process indicators as defined by the World Health Organization (WHO): 1) Availability of formal written terms of reference; 2) Legislative or administrative basis establishing the committee; 3) Core membership with at least 5 main expertise areas represented among members; 4) Committee meets at least once a year; 5) Agenda and expectations from the committee together with background materials distributed at least a week ahead of meetings; 6) Declaration of interests by committee members. NITAGs review all available scientific and programmatic data to arrive at policy decisions, also taking into consideration local surveillance data.

[2] All Gavi supported countries should have a National Regulatory Authority (NRA) able to perform registration of vaccines, assess vaccine performance through post-marketing surveillance, and assess and inspect clinical trials conducted in their country. There are 10 producing countries where functional NRAs are essential to meet future global demand and develop or sustain pre-qualified products. Support will be concentrated on a first group of these countries with high potential to increase supply and will be extended to other countries about to introduce NUV and where clinical trials have been conducted (mostly in Africa, some in Asia, Central Europe, and South America).

[3]Coverage data are used to prioritise country support and to concentrate efforts to strengthen immunisation systems. 40% of Gavi-supported countries currently have more than a 5 percentage point difference between DTP3 coverage estimates and WHO/UNICEF estimates.

[4]Includes communication plan, fact sheets, media advisory, press release, advocate plans, etc. Assumes five communication packets developed per annum based on previous trends.

[5] Does not include Comprehensive Multi-year Plans for Immunisation (cMYPs). Work on cMYPs is included in Strategic goal 3.

[6] Source: Country Annual Progress Reports (APRs)

[7]Assessment of successful introduction is based on a checklist including the following: Independent Review Committee-endorsed introduction plan, appropriate training of health care workers, adaptation of Expanded Programme of Immunization (EPI) materials and guidelines, cold chain inventory, Effective Vaccine Management (EVM) assessment, community mobilisation, and coverage monitoring.

[8]Surveillance data quality indicators as defined by WHO ( Surveillance systems are used for generation of local data for decision-making, provision of impact data to sustain domestic and external financing subsequent to Gavi support, monitoring of changes in disease epidemiology (e.g. genotype and serotype shifts), provision of data for burden of disease and cost-effectiveness analyses, outbreak detection and response, monitoring of and appropriate response to adverse events.

close icon

modal window here